Business
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"RADNOR, Pa., Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates (\"6th Annual NIF\"). The forum takes place Sunday, January 8, 2023, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference being held in San Francisco. The forum is open to registered attendees and a link to the presentation content is expected to be available on the NRx Pharmaceuticals' website.\n\n \n \n \n \n \n \n\n \nInvestors wishing to meet with NRx Pharmaceuticals' executives during the upcoming JP Morgan Healthcare Conference in San Francisco are invited to contact the Company's investor relations representatives.\nAbout NRx PharmaceuticalsClinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's NMDA receptor and is being investigated in a Phase 3 trial under an FDA Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and suicidal ideation, an indication for which the only approved treatment is electroshock therapy. NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine.\nCautionary Note Regarding Forward-Looking StatementsThis announcement of NRx Pharmaceuticals, Inc. includes \"forward-looking statements\" within the meaning of the \"safe harbor\" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, stateme...